Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of ...
YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Single dose of YOLT-202 was well tolerated with a favorable safety profile YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results